Santen JV To Become China’s ‘Largest Ophthalmic Site’
This article was originally published in PharmAsia News
Executive Summary
Another Japanese company is building its Chinese presence through a local partnership, this time eye care specialist Santen, which is planning to link with a state-owned company in Chongqing.
You may also be interested in...
Potential Santen, Centaur India Eye Care Alliance Off
Indian firm Centaur confirms to Scrip that a planned alliance with Santen for the Indian market is not going ahead, as the mid-sized Japanese ophthalmic specialist says it is looking to build up its direct presence in Asia.
Hisun-Pfizer Split: What Went Wrong And What Next?
The breakup of the Hisun-Pfizer JV typifies an unhappy marriage between Chinese and MNC pharma firms in the generics segment in recent years, although the two companies will continue to work as commercial partners under a new framework. Scrip delves into the reasons for the split and also outlines why, China is, nevertheless, expected to see more joint ventures for innovative drugs.
China Options For Takeda As It Pursues Emerging Markets Buy
Takeda’s recent revelation that it had set aside around $450m for a planned M&A transaction in an undisclosed emerging market has triggered speculation about where and how the company might spend its money. Might China be in the mix?